Koers Bio-Path Holdings Inc Nasdaq
Aandelen
US09057N1028
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | - | Omzet 2025 * | - | Marktkapitalisatie | 3,4 mln. 3,13 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -13 mln. -11,98 mln. | Nettowinst (verlies) 2025 * | -14 mln. -12,9 mln. | EV/omzet 2024 * | - |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | - |
K/w-verhouding 2024 * |
-0,22
x | K/w-verhouding 2025 * |
-0,27
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 99,9% |
Recentste transcriptie over Bio-Path Holdings Inc
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Founder | - | 10-05-07 | |
Peter Nielsen
CEO | Chief Executive Officer | 75 | 10-05-07 |
Douglas Morris
FOU | Founder | 68 | 10-05-07 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Douglas Morris
FOU | Founder | 68 | 10-05-07 |
Heath Cleaver
BRD | Director/Board Member | 51 | 11-02-14 |
Peter Nielsen
CEO | Chief Executive Officer | 75 | 10-05-07 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+41,79% | 50,93 mld. | |
-0,56% | 42,12 mld. | |
+49,62% | 42,05 mld. | |
-7,20% | 29,18 mld. | |
+12,59% | 26,02 mld. | |
-21,51% | 18,9 mld. | |
+6,92% | 13,21 mld. | |
+24,91% | 12,17 mld. | |
+29,60% | 12,16 mld. |